Why pain and physical medicine groups separate vendor review from clinical decisions
Pain management and physical medicine practices generally keep vendor qualification distinct from any clinical decision about intended use. Vendor qualification asks what documentation a supplier can produce - certificate of analysis, donor eligibility summary, lot release record - and whether ordering access is restricted to verified licensed accounts.
The clinical question of whether a specific use fits within 21 CFR 1271.10 for Wharton's jelly products, or how an exosome product offered outside the 361 framework should be handled, stays with the treating physician and that physician's own counsel.
Scranton
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
25- Pain Medicine
- 7
- Physical Medicine & Rehabilitation
- 18
Logistics for a Northeast practice
Cryopreserved Wharton's jelly formats are shipped overnight on dry ice in validated containers and require prompt transfer to -80 degree C storage on arrival; lyophilized Wharton's jelly and exosome formats are shelf-stable and are handled according to the insert supplied with each lot. A practice should plan a receiving process that logs each lot identifier against the patient record so product use stays traceable.
Confirming standing before ordering
Pennsylvania practices adding a new biologics line typically confirm their own standing with the Pennsylvania State Board of Medicine (or the relevant board for their license type) and review the purchase with counsel, since neither registration under a federal framework nor a supplier's documentation substitutes for that review. Precision Biologics does not provide clinical, dosing, or protocol advice; its role is supplying product and supporting documentation.
Opening a verified account
Accounts are verified against an NPI number before ordering access or verified-account pricing is released. Once verified, a practice can request the full documentation set for a given lot and schedule a physician-level call to review that documentation; those calls address specifications and paperwork, not treatment decisions.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Does Precision Biologics ship directly to Scranton practices?+
Yes. Orders from verified accounts ship nationally, including to pain management and physical medicine practices in Scranton, using overnight cold-chain shipping for cryopreserved formats.
What does the count of 25 providers refer to?+
It is the number of individually registered NPI-1 providers with a Scranton practice location and a Pain Medicine or Physical Medicine & Rehabilitation taxonomy in the NPPES registry as of 2026-10-27 - a registry count, not a lead list or demand estimate.
Who decides whether a product fits a specific use?+
The ordering physician and that physician's own regulatory counsel. Precision Biologics supplies product and documentation and does not advise on clinical use, dosing, or protocols.